Cardiology Headline News

In this Healio video exclusive, Michael S. Garshick, MD, MS, discusses the role of inflammation in heart disease and how it has become a treatment target.

Return-to-play considerations and CVD risks of people who perform under life-threatening conditions were among the key sports cardiology topics at the American College of Cardiology Scientific Session in April in Atlanta.

Patients with atherosclerosis and elevated LDL plus autoimmune or inflammatory disease may derive particular CV benefit from PCSK9 inhibition with evolocumab, a speaker reported.

Improving HDL function may improve outcomes after acute MI for patients with multivessel disease and high LDL, according to a subanalysis of the AEGIS II trial presented at the National Lipid Association Scientific Sessions.

Due to demographic changes and a rise in risk factors, the prevalence and economic burden of heart disease and stroke in the United States are expected to increase dramatically by 2050, according to the American Heart Association.

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final results of the phase 2b SHASTA-2 trial.

SAN ANTONIO — Infection preventionists repurposed an existing intervention that eliminated bloodstream infections completely among patients receiving extracorporeal membrane oxygenation in the cardiothoracic ICU.

Surgical faculty and trainees report having a negative psychological impact associated with adverse events in their patients, according to results from a mixed-methods study and survey.

In this Healio video exclusive, Joel M. Gelfand, MD, MSCE, discusses the connection between psoriasis and cardiovascular outcomes.

In this Healio video exclusive, a speaker at the National Lipid Association Scientific Sessions discusses opportunities for heart disease prevention in women at the time of menopause transition.